Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
109 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The U.S. IVD for autoimmune diseases market was valued at USD 4.0 billion in 2015 and is expected to reach a value of USD 4.74 billion by 2024 .The U.S. Laboratory Developed Test (LDT) for autoimmune diseases was valued at USD 830.9 million in 2015. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market. These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion. A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth. It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories. The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests. Further Key Findings from the Study Suggest: In 2015, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 14.05% and the LDT for rheumatoid arthritis had a share of 13.2%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share. In 2015, clinical chemistry was the leading segment with a market share of 35.6% in the IVD and 34.1% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share. Some key participants in this field include Becton, Dickinson and Company; Roche Diagnostics; Abbott Laboratories; Bio-Rad Laboratories, Inc.; Danaher Corporation; SQI Diagnostics; Omega Diagnostics Group PLC; ThermoFisher Scientific, Inc.; and some others. The key players focus specially on developing innovative solutions for diagnosis. The laboratories and institutes such as Mayo Medical Laboratories, Oklahoma Medical Research Foundation, and Moleculera Labs also operate in the U.S. in the same domain.
Table of Content
s Chapter 1 Research Methodology 1.1 Information Procurement 1.1.1 Purchased database: 1.1.2 GVR's internal database 1.2 Primary Research: 1.2.1 List of Primary Sources Include: Chapter 2 Executive Summary Chapter 3 Market Snapshot Chapter 4 Market Variables, Trends & Scope 4.1 Market Segmentation & Scope 4.1.1 Market Driver Analysis 4.1.2 Growing Prevalence of Autoimmune Diseases 4.1.3 Increasing Demand for Personalized Medicine 4.1.4 Introduction of Technological Advancements 4.2 Market Restraint Analysis 4.2.1 Low research budget for autoimmune diseases 4.3 Key Opportunities Prioritized 4.4 U.S. Lab Test IVD for Autoimmune Disease Diagnostics Market- SWOT Analysis, by Factor 4.5 Industry Analysis - Porter's 4.6 Technology Trends 4.7 Competitive Analysis/Heat Map Analysis 2015 Chapter 5 Market Categorization 1: Application Estimates & Trend Analysis 5.1 U.S. Lab Test IVD for Autoimmune Disease Diagnostics Market: Application Movement Analysis 5.2 U.S. Lab Test LDT for Autoimmune Disease Diagnostics Market: Application Movement Analysis 5.3 Addison's Disease 5.3.1 U.S. lab test IVD for Addison's disease diagnostics market, 2013 - 2024 (USD Million) 5.3.2 U.S. lab test LDT for Addison's disease diagnostics market, 2013 - 2024 (USD Million) 5.4 Ankylosing Spondylitis (AS) 5.4.1 U.S. lab test IVD for AS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.4.2 U.S. lab test LDT for AS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.5 Alopecia Areata 5.5.1 U.S. lab test IVD for alopecia areata diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.5.2 U.S. lab test LDT for alopecia areata diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.6 Rheumatoid Arthritis (RA) 5.6.1 U.S. lab test IVD for RA diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.6.2 U.S. lab test LDT for RA diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.7 Systemic Lupus Erythematosus (SLE) 5.7.1 U.S. lab test IVD for SLE diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.7.2 U.S. lab test LDT for systemic lupus erythematosus diagnostics market, 2013 - 2024 (USD Million) 5.8 Systemic Sclerosis 5.8.1 U.S. lab test IVD for systemic sclerosis diagnostics market estimates, 2013 - 2024 (USD Million) 5.8.2 U.S. lab test LDT for systemic sclerosis diagnostics market estimates, 2013 - 2024 (USD Million) 5.9 Psoriasis 5.9.1 U.S. lab test IVD for psoriasis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.9.2 U.S. lab test LDT for psoriasis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.10 Antiphospholipid Antibody Syndrome (APS) 5.10.1 U.S. lab test IVD for APS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.10.2 U.S. lab test LDT for APS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.11 Diabetes Type 1 (T1D) 5.11.1 U.S. lab test IVD for diabetes type 1 diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.11.2 U.S. lab test LDT for diabetes type 1 diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.12 Crohn's Disease 5.12.1 U.S. lab test IVD for Crohn's disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.12.2 U.S. lab test LDT for Crohn's disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.13 Ulcerative Colitis 5.13.1 U.S. lab test IVD for ulcerative colitis diagnostics market estimates, 2013 - 2024 (USD Million) 5.13.2 U.S. lab test LDT for ulcerative colitis diagnostics market estimates, 2013 - 2024 (USD Million) 5.14 Narcolepsy 5.14.1 U.S. lab test IVD for narcolepsy diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.14.2 U.S. lab test LDT for narcolepsy diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.15 Multiple Sclerosis (MS) 5.15.1 U.S. lab test IVD for multiple sclerosis diagnostics market estimates, 2013 - 2024 (USD Million) 5.15.2 U.S. lab test LDT for multiple sclerosis diagnostics market estimates, 2013 - 2024 (USD Million) 5.16 Uveitis 5.16.1 U.S. lab test IVD for uveitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.16.2 U.S. lab test LDT for uveitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.17 Others 5.17.1 U.S. lab test IVD for others diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 5.17.2 U.S. lab test LDT for others diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) Chapter 6 Market Categorization 2: Technology Estimates & Trend Analysis 6.1 U.S. Lab Test IVD for Autoimmune Disease Diagnostics Market: Technology Movement Analysis 6.2 U.S. Lab Test LDT for Autoimmune Disease Diagnostics Market: Technology Movement Analysis 6.3 Immunoassays 6.3.1 U.S. lab test IVD for Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million) 6.3.2 U.S. lab test LDT for Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million) 6.4 Clinical Chemistry 6.4.1 U.S. lab test IVD for clinical chemistry market estimates and forecasts, 2013 - 2024 (USD Million) 6.4.2 U.S. lab test LDT for clinical chemistry market estimates and forecasts, 2013 - 2024 (USD Million) 6.5 Hematology 6.5.1 U.S. lab test IVD for hematology market estimates and forecasts, 2013 - 2024 (USD Million) 6.5.2 U.S. lab test LDT for hematology market estimates and forecasts, 2013 - 2024 (USD Million) 6.6 Coagulation 6.6.1 U.S. lab test IVD for coagulation market estimates and forecasts, 2013 - 2024 (USD Million) 6.6.2 U.S. lab test LDT for coagulation market estimates and forecasts, 2013 - 2024 (USD Million) 6.7 Microbiology 6.7.1 U.S. lab test IVD for microbiology market estimates and forecasts, 2013 - 2024 (USD Million) 6.7.2 U.S. lab test LDT for microbiology market estimates and forecasts, 2013 - 2024 (USD Million) 6.8 Molecular Diagnostics 6.8.1 U.S. lab test IVD for molecular diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) 6.8.2 U.S. lab test LDT for molecular diagnostics market estimates and forecasts, 2013 - 2024 (USD Million) Chapter 7 Competitive Landscape 7.1 Company Profiles 7.1.1 Abbott 7.1.1.1 Company overview 7.1.1.2 Financial performance 7.1.1.3 Product benchmarking 7.1.1.4 Strategic initiatives 7.1.2 Roche Diagnostics 7.1.2.1 Company overview 7.1.2.2 Financial performance 7.1.2.3 Product benchmarking 7.1.2.4 Strategic initiatives 7.1.3 Siemens Healthcare GmbH 7.1.3.1 Company Overview 7.1.3.2 Financial Performance 7.1.3.3 Product Benchmarking 7.1.3.4 Strategic Initiatives 7.1.4 Beckman Coulter, Inc. 7.1.4.1 Company Overview 7.1.4.2 Financial Performance 7.1.4.3 Product Benchmarking 7.1.4.4 Strategic Initiatives 7.1.5 SQI Diagnostics 7.1.5.1 Company Overview 7.1.5.2 Financial Performance 7.1.5.3 Product Benchmarking 7.1.5.4 Strategic Initiatives 7.1.6 Alere 7.1.6.1 Company Overview 7.1.6.2 Financial Performance 7.1.6.3 Product Benchmarking 7.1.6.4 Strategic Initiatives 7.1.7 Bio-Rad Laboratories, Inc. 7.1.7.1 Company Overview 7.1.7.2 Financial Performance 7.1.7.3 Product Benchmarking 7.1.7.4 Strategic Initiatives 7.1.8 Becton, Dickinson & Company 7.1.8.1 Company Overview 7.1.8.2 Financial Performance 7.1.8.3 Product Benchmarking 7.1.8.4 Strategic Initiatives 7.1.9 Omega Diagnostics Group PLC 7.1.9.1 Company Overview 7.1.9.2 Financial Performance 7.1.9.3 Product Benchmarking 7.1.10 Thermo Fisher Scientific Inc. 7.1.10.1 Company Overview 7.1.10.2 Financial Performance 7.1.10.3 Product Benchmarking 7.1.10.4 Strategic Initiatives 7.1.11 Mayo Medical Laboratories 7.1.11.1 Company Overview 7.1.11.2 Financial Performance 7.1.11.3 Product Benchmarking 7.1.11.4 Strategic Initiatives 7.1.12 Oklahoma Medical Research Foundation (OMRF) 7.1.12.1 Company Overview 7.1.12.2 Financial Performance 7.1.12.3 Product Benchmarking 7.1.13 Moleculera Labs 7.1.13.1 Company Overview 7.1.13.2 Financial Performance 7.1.13.3 Product Benchmarking 7.1.13.4 Strategic Initiatives
List of Tables
TABLE 1 List of Autoimmune Diseases and its impact on the U.S. population TABLE 2 Comparative Analysis of NIH funding
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
